Nuvalent Highlights New Data Exhibiting Expanded Preclinical Activity Of NVL-520 In ROS1-Driven Cancers


Nuvalent Inc NUVL announced new data on NVL-520 and NVL-655, central nervous system (CNS)-penetrant kinase inhibitors, at the American Association for Cancer Research (AACR) Annual Meeting.

  • NVL-520 shows high activity against diverse ROS1 fusion partners tested and induces regression in a ROS1-driven model of glioblastoma harboring GOPC(L)-ROS1.
  • NVL-655 shows strong activity in diverse preclinical models of ALK-driven cancers, including cholangiocarcinoma, neuroblastoma, lymphoma, and soft-tissue sarcoma.
  • NVL-655 exhibits activity for diverse ALK oncoproteins among all inhibitors tested, including fusions, point mutations, and partial N-terminal deletions.
  • NVL-520 is currently in the Phase 1 portion of the Phase 1/2 ARROS-1 study for advanced ROS1-positive NSCLC and other solid tumors. 
  • Nuvalent recently announced the IND clearance for NVL-655 and plans to initiate the Phase 1 portion of the Phase 1/2 ALKOVE-1 study for advanced ALK-positive NSCLC and other solid tumors in Q2 of 2022. 
  • Nuvalent is also advancing a discovery pipeline with plans to nominate two new development candidates in 2022 for ALK IXDN compound mutations and HER2 exon 20 insertions.
  • Price Action: NUVL shares closed 3.87% higher at $13.15 on Friday
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!